5 Best Stocks to Buy Today
Company (Ticker) | 12 Week Price Change | Forward PE | Price | Proj EPS Growth (1 Year) | Projected Sales Growth (1Y) |
---|---|---|---|---|---|
Remitly Global (RELY) | -6.86% | 133.58 | $16.54 | 163.16% | 27.90% |
Kiniksa Pharmaceuticals International, plc (KNSA) | 44.19% | 37.61 | $38.85 | 272.78% | 50.38% |
BeOne Medicines Ltd. - Sponsored ADR (ONC) | 8.18% | 153.17 | $315.74 | 133.99% | 36.06% |
OPENLANE, Inc. (KAR) | 6.91% | 22.72 | $26.95 | 37.06% | 5.56% |
Coeur Mining (CDE) | 142.35% | 25.62 | $18.48 | 377.78% | 88.25% |
*Updated on October 21, 2025.
Stock #1
Remitly Global (RELY)
$16.54 USD +0.51 (3.18%)
3-Year Stock Price Performance

Premium Research for RELY
- Zacks Rank
Strong Buy 1
- Style Scores
C Value A Growth F Momentum B VGM
- Market Cap:$3.31B (Mid Cap)
- Projected EPS Growth:163.16%
- Last Quarter EPS Growth:-20.00%
- Last EPS Surprise:NA
- Next EPS Report date: Oct. 29, 2025
Our Take:
Remitly is a digital cross-border payments provider serving immigrants and global workers through a mobile-first remittance platform.
Its Zacks Rank #1 alongside Style Scores of C for Value, A for Growth, and F for Momentum, as well as a VGM Score of B, reflects strong earnings growth prospects even if recent price action has been choppy. Remitly’s execution supports that, with Q2 2025 results surpassing guidance with 34% revenue growth, positive GAAP profitability, and a higher full-year outlook. New initiatives, such as Remitly Business for SMB cross-border payments and the Remitly One membership, expand the addressable market beyond consumer remittances, adding diversified growth drivers.
On the chart, the stock’s pullbacks contrast with steadily improving 2026–2027 EPS consensus, supporting the Rank’s signal that estimate revisions, not short-term momentum, are the key near-term catalyst. If execution on new products persists, estimate revisions should continue to anchor the shares.
Stock #2
Kiniksa Pharmaceuticals International, plc (KNSA)
$38.85 USD -0.14 (-0.36%)
3-Year Stock Price Performance

Premium Research for KNSA
- Zacks Rank
Strong Buy 1
- Style Scores
D Value A Growth A Momentum B VGM
- Market Cap:$2.89B (Mid Cap)
- Projected EPS Growth: 273.33%
- Last Quarter EPS Growth:109.09%
- Last EPS Surprise:27.78%
- Next EPS Report date: Nov. 4, 2025
Our Take:
Kiniksa is a biopharma company whose lead product, ARCALYST (rilonacept), treats recurrent pericarditis, the first FDA-approved therapy for this indication.
A Zacks Rank #1 with Style Scores of D for Value, A for Growth and Momentum, and a VGM Score of B fits a fundamentals-led acceleration story. ARCALYST revenue rose sharply in Q2 2025, and guidance for 2025 was raised again after a strong quarter, while Kiniksa remains cash-flow positive. The Regeneron-originated medicine gives Kiniksa a durable commercial base as the company advances additional cardio-inflammation assets.
The chart shows price tracking higher with visible step-ups in 2026–2027 consensus EPS, consistent with estimate upgrades driving the Rank. Given category leadership in a defined patient population and growing duration on therapy, Kiniksa’s setup remains attractive, albeit with typical biotech execution risks.
Stock #3
BeOne Medicines Ltd. - Sponsored ADR (ONC)
$315.74 USD -2.86 (-0.90%)
3-Year Stock Price Performance

Premium Research for ONC
- Zacks Rank
Strong Buy 1
- Style Scores
D Value A Growth A Momentum B VGM
- Market Cap:$34.92B (Large Cap)
- Projected EPS Growth:133.99%
- Last Quarter EPS Growth: -31.15%
- Last EPS Surprise:75.00%
- Next EPS Report date:Nov. 11, 2025
Our Take:
BeOne Medicines (formerly BeiGene) is a global oncology company commercializing BRUKINSA and other cancer therapies while advancing a broad hematology/oncology pipeline.
The Zacks Rank #1 and Style Scores of D for Value, A for Growth and Momentum, as well as a VGM Score of B, align with accelerating earnings from strong BRUKINSA sales and pipeline optionality, including the BCL-2 inhibitor sonrotoclax. Recent results highlight robust profitability improvements following the rebrand and redomicile.
On the chart, ONC’s uptrend coincides with rising 2026–2027 EPS estimates, a classic confirmation of estimate-driven momentum behind a Rank #1 stock. With multiple approved products and late-stage programs, BeOne offers a diversified growth engine, though regulatory and competitive dynamics remain key watch items.
Stock #4
OPENLANE, Inc. (KAR)
$26.95 USD +0.48 (1.81%)
3-Year Stock Price Performance

Premium Research for KAR
- Zacks Rank
Strong Buy 1
- Style Scores
B Value D Growth B Momentum B VGM
- Market Cap: $2.81B (Mid Cap)
- Projected EPS Growth: 37.65%
- Last Quarter EPS Growth: 6.45%
- Last EPS Surprise: 37.50%
- Next EPS Report date: Nov. 5, 2025
Our Take:
OPENLANE runs digital marketplaces that link commercial sellers and auto dealers for wholesale used vehicle transactions, leveraging an asset-light, fee- and service-driven business model.
A Zacks Rank #1 (Strong Buy) signals upward earnings estimate revisions, while its Style Scores of B for Value, D for Growth, and A for Momentum, as well as a VGM Score of B point to reasonable valuation, modest fundamental growth, and strong price action, which is often a constructive setup when a marketplace is scaling. The company’s fundamentals back that view: Q2 2025 showed 21% dealer-to-dealer volume growth, 24% growth in higher-margin auction fees, rising free cash flow, and raised full-year guidance, underscoring operating leverage in the platform.
The Price, Consensus & EPS Surprise chart shows price inflecting higher alongside rising 2026–2027 consensus EPS, a pattern consistent with estimate momentum supporting the Zacks Rank. With the strategy squarely on digital transaction growth after past portfolio simplification, OPENLANE offers near-term catalysts tied to volumes, mix, and earnings revisions.
Stock #5
Coeur Mining (CDE)
$18.48 USD -3.55 (-16.11%)
3-Year Stock Price Performance

Premium Research for CDE
- Zacks Rank
Strong Buy 1
- Style Scores
F Value B Growth D Momentum D VGM
- Market Cap:$14.16B (Large Cap)
- Projected EPS Growth:377.78%
- Last Quarter EPS Growth:81.82%
- Last EPS Surprise: 11.11%
- Next EPS Report date: Oct. 29, 2025
Our Take:
Coeur Mining is a North American precious metals producer with operations in Palmarejo (Mexico), Kensington (Alaska), Wharf (South Dakota), and the expanded Rochester mine in Nevada.
Its Zacks Rank #1 with Style Scores of F for Value, B for Growth, D for Momentum, as well as a VGM Score of D, suggests estimates revision is the primary near-term driver despite mixed valuation and momentum signals. Fundamentals have improved with Rochester reporting record Q2 2025 revenue, operating cash flow, and net income, while reaffirming full-year guidance and strengthening the balance sheet.
The chart shows a recovering share price alongside steadily rising 2026–2027 EPS consensus, consistent with mine ramp-up benefits and better metal price leverage. Investors should watch execution at Rochester and commodity volatility, but estimate revisions remain supportive.
Best Stocks to Buy Now: How to Use This List
It’s important to understand what this list is, and what it isn’t.
For decades, the Zacks Rank has been a proven system that has helped investors identify stocks most likely to outperform. Instead of relying on hunches or hype, it’s grounded in earnings estimate revisions — a factor strongly correlated with stock price movement. When combined with additional fundamental metrics, the approach becomes even more powerful.
Still, it’s important to understand these basics:
- While the list offers exposure across several industries, it is not a fully diversified portfolio. You should think of it as a starting point, not a complete investing strategy.
- Even though these stocks are backed by a proven system, nothing protects you from short-term downside. Depending on market conditions, most — or even all — could decline in the near term.
- The Zacks Rank works because it captures trends in earnings momentum. That power plays out over weeks and months, not days. Investors with patience and discipline are more likely to benefit.
- Before buying any single stock, check how it aligns with your goals, risk tolerance, and broader portfolio.
Methodology
The Zacks Rank is a proprietary stock-rating model that uses trends in earnings estimate revisions and earnings-per-share (EPS) surprises to classify stocks into five groups: #1 (Strong Buy), #2 (Buy), #3 (Hold), #4 (Sell) and #5 (Strong Sell). The Zacks Rank is calculated through four primary factors related to earnings estimates: analysts' consensus on earnings estimate revisions, the magnitude of revision change, the upside potential and estimate surprise (or the degree in which earnings per share deviated from the previous quarter).
Zacks builds the data from 3,000 analysts at over 150 different brokerage firms. The average yearly gain for Zacks Rank #1 (Strong Buy) stocks is +23.62% per year from January, 1988, through June 2, 2025.
For this list, only companies in the top 50% of industries that have average daily trading volumes of 100,000 shares or more were considered. Stocks with a share value of $5 or less were excluded. These companies earned Zacks Rank #1 (Strong Buy) between Oct. 4 and Oct. 17, 2025. All information is current as of market open, Oct. 20, 2025.
Common Questions of New Investors
Where to Buy Stocks
To invest in stocks, you must open a brokerage account, fund the account and purchase stocks through your selected brokerage. Investors may also purchase stocks through a financial advisor or an automated robo advisor. Some publicly traded companies also offer a direct stock purchase plan, where you can purchase shares directly from the company.
Alternative Ways to Invest in Stocks
You can also invest in stock funds, such as mutual funds, index funds and exchange-traded funds, where the fund managers select the pool of stocks that follow an investing strategy. These funds may broadly cover an entire index, such as the S&P 500, or specific types of stocks, such as industries like technology and energy companies, company size such as small cap companies, or location like international companies.
How to Start Investing in Stocks Today
It’s easy to start investing by opening an online brokerage account. Opening a standard brokerage account takes about 20 minutes and you’ll need to have some personal information ready, such as your social security number and your bank details to fund your account.
You’ll need to decide whether to open a taxable account (most common), a tax-deferred retirement account such as a traditional IRA or a tax-free retirement account such as a Roth IRA, which is funded with after-tax dollars, but qualified withdrawals are tax-free. A margin account allows for borrowing to purchase stocks and is best for experienced traders.
Set goals before you begin investing – determine how much you can afford to invest and your tolerance for risk.
What to Look for When You Buy Stocks?
The goal in all equities investment is to buy low and sell high, growing your wealth over time. Researching the companies to invest in is key – what kind of product or service do they offer? How do they compare with competitors? How fast are they growing? Does the stock pay regular dividends to shareholders? Does the stock help diversify your portfolio by giving you exposure to a market segment you currently don’t hold?
Understanding fundamental analysis can help determine whether the stock has the potential for growth at its current purchase price. Factors that can help determine that include earnings per share (EPS), price-to-earnings ratio and PE growth. Technical analysis is used looking at statistical patterns to potentially predict future price moves. Some investors may look for a growth and income strategy, looking for stocks with solid revenues that pay good dividends, or a value strategy, looking if a current stock price is below what their revenue, EPS and other factors suggest.
Analysts also often look for the momentum of a stock by looking at moving averages of a stock's closing price over a 50-day, 100-day or 12-month trailing time period to determine signals whether to buy or sell a stock.